{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:44:31Z","timestamp":1790948671528,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF\\u20132022R1A2C1003070"],"award-info":[{"award-number":["NRF\\u20132022R1A2C1003070"]}],"id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijbiomac.2025.149572","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T23:51:35Z","timestamp":1765237895000},"page":"149572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Development of selumetinib\u2013loaded solid dispersion based on low molecular weight methylcellulose for the enhanced solubility, stability, dissolution, and bioavailability"],"prefix":"10.1016","volume":"337","author":[{"given":"Jun Hak","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Pil","family":"Jee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Jae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Sung","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan Hyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.149572_bb0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"Ferner","year":"2007","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0015","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","article-title":"Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1","volume":"20","author":"Gross","year":"2018","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0020","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1\u2013associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jpepsy\/jsr124","article-title":"Social\u2013emotional functioning of children and adolescents with neurofibromatosis type 1 and plexiform neurofibromas: relationships with cognitive, disease, and environmental variables","volume":"37","author":"Martin","year":"2012","journal-title":"J. Pediatr. Psychol."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40265-020-01331-x","article-title":"Selumetinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.spen.2006.01.005","article-title":"Clinical manifestations and management of neurofibromatosis type 1","volume":"13","author":"Tonsgard","year":"2006","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA\u2013approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/13543784.2015.982275","article-title":"Selumetinib for the treatment of cancer","volume":"24","author":"Ciombor","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0050","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-022-00687-0","article-title":"State of the art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references","volume":"24","author":"Bocci","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40495-020-00230-9","article-title":"A review of current methods for food effect prediction during drug development","volume":"6","author":"Zhang","year":"2020","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11095-022-03339-2","article-title":"Physiologically based biopharmaceutics model for Selumetinib food effect investigation and capsule dissolution safe space \u2013 part I: adults","volume":"40","author":"Pepin","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0065","unstructured":"ClinicalsTrials.gov, Search for: Selumetinib, Phase:3. https:\/\/clinicaltrials.gov\/search?intr= Selumetinib &aggFilters=phase:3, 2025 (accessed 25 August 2025)."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0070","first-page":"1","article-title":"Mechanistic insights into amorphous solid dispersions: bridging theory and practice in drug delivery","volume":"42","author":"S. B","year":"2025","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.149572_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081694","article-title":"Development of alectinib\u2013suspended SNEDDS for enhanced solubility and dissolution","volume":"14","author":"Park","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0080","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12272-014-0399-0","article-title":"Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability","volume":"38","author":"Pradhan","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104259","article-title":"An investigation into solubility and dissolution improvement of alectinib hydrochloride as a third\u2013generation amorphous solid dispersion","volume":"81","author":"Saha","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16070958","article-title":"Investigation of stabilized amorphous solid dispersions to improve Oral Olaparib absorption","volume":"16","author":"Yun","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0095","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1208\/s12248-017-0052-1","article-title":"Advantageous solubility\u2013permeability interplay when using amorphous solid dispersion (ASD) formulation for the BCS class IV P\u2013gp substrate rifaximin: simultaneous increase of both the solubility and the permeability","volume":"19","author":"Beig","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0100","series-title":"Pharmaceutical Amorphous Solid Dispersions","author":"Newman","year":"2015"},{"issue":"3 Pt B","key":"10.1016\/j.ijbiomac.2025.149572_bb0105","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ejpb.2013.09.007","article-title":"Current trends and future perspectives of solid dispersions containing poorly water\u2013soluble drugs","volume":"85","author":"Vo","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0110","article-title":"Trends in amorphous solid dispersion drug products approved by the U.S. food and drug administration between 2012 and 2023","volume":"7","author":"Moseson","year":"2024","journal-title":"Int. J. Pharm. X"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.149572_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/gels10120837","article-title":"Supersaturated gel formulation (SGF) of atorvastatin at a maximum dose of 80 mg with enhanced solubility, dissolution, and physical stability","volume":"10","author":"Park","year":"2024","journal-title":"Gels"},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0120","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1166\/jnn.2020.17641","article-title":"Preparation and characterization of tenofovir disoproxil\u2013loaded enteric microparticle","volume":"20","author":"Kim","year":"2017","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0125","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4155\/bio-2016-0082","article-title":"Determination of selumetinib, N\u2013desmethyl selumetinib and selumetinib amide in human biological samples by LC\u2013MS\/MS","volume":"8","author":"Severin","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0130","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpba.2017.01.020","article-title":"Development and validation of a liquid chromatography\u2013tandem mass spectrometry method for the assay of tafamidis in rat plasma: application to a pharmacokinetic study in rats","volume":"137","author":"Hyun","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0135","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00280-011-1732-7","article-title":"A phase I, open\u2013label, randomized crossover study to assess the effect of dosing of the MEK 1\/2 inhibitor Selumetinib (AZD6244; ARRY\u2013142866) in the presence and absence of food in patients with advanced solid tumors","volume":"68","author":"Leijen","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jps.22259","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride","volume":"100","author":"Olivera","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149572_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030950","article-title":"The development of super\u2013saturated rebamipide eye drops for enhanced solubility, stability, patient compliance, and bioavailability","volume":"15","author":"Jang","year":"2023","journal-title":"Pharmaceutics"},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.149572_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29225267","article-title":"Supersaturated liquid formulation of Pazopanib hydrochloride loaded with synergistic precipitation inhibitors","volume":"29","author":"Park","year":"2024","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.149572_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/polym11111772","article-title":"Crosslinking kinetics of methylcellulose aqueous solution and its potential as a scaffold for tissue engineering","volume":"11","author":"Niemczyk\u2013Soczynska","year":"2019","journal-title":"Polymers (Basel)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149572_bb0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bcp.13404","article-title":"Population pharmacokinetics of the MEK inhibitor selumetinib and its active N\u2013desmethyl metabolite: data from 10 phase I trials","volume":"84","author":"Patel","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0165","article-title":"Impurities: Guideline for residual solvents Q3C (R8)","volume":"4","author":"Guideline","year":"2021","journal-title":"Current Step"},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0170","first-page":"1681","article-title":"The role of the carrier in the formulation of pharmaceutical solid dispersions","volume":"13","author":"Van Duong","year":"2016","journal-title":"Part II: amorphous carriers, Expert Opin Drug Deliv"},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0175","doi-asserted-by":"crossref","first-page":"359","DOI":"10.34172\/apb.2020.044","article-title":"A review on solid dispersion and carriers used therein for solubility enhancement of poorly water soluble drugs","volume":"10","author":"Tekade","year":"2020","journal-title":"Adv Pharm Bull"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149572_bb0180","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.xphs.2022.12.008","article-title":"Biorelevant dissolution method considerations for the appropriate evaluation of amorphous solid dispersions: are two stages necessary?","volume":"112","author":"Wang","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149572_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106086","article-title":"Role of polymers in the physical and chemical stability of amorphous solid dispersion: a case study of carbamazepine","volume":"169","author":"Yu","year":"2022","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025101293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025101293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T21:02:38Z","timestamp":1768942958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025101293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":37,"alternative-id":["S0141813025101293"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149572","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of selumetinib\u2013loaded solid dispersion based on low molecular weight methylcellulose for the enhanced solubility, stability, dissolution, and bioavailability","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149572"}}